title: Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.
authors.forename: Eric
authors.initials: E
authors.lastname: Winquist
authors.forename: Jim A
authors.initials: JA
authors.lastname: Julian
authors.forename: Malcolm J
authors.initials: MJ
authors.lastname: Moore
authors.forename: Abdenour
authors.initials: A
authors.lastname: Nabid
authors.forename: Jinka
authors.initials: J
authors.lastname: Sathya
authors.forename: Lori
authors.initials: L
authors.lastname: Wood
authors.forename: Peter
authors.initials: P
authors.lastname: Venner
authors.forename: Mark
authors.initials: M
authors.lastname: Levine
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy*; D002369:Castration; D004311:Double-Blind Method; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use*; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011788:Quality of Life; D011994:Recombinant Proteins; D054556:Venous Thromboembolism / Q000139:chemically induced
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa